• PDB45 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS): RESOURCE USE AND DIRECT COSTS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Clinical Outcomes

    Nov 1, 2019, 00:00

  • Medical Devices - Medical Technologies

    Nov 1, 2019, 00:00

  • Infectious Diseases - Economic Evaluation

    Nov 1, 2019, 00:00

  • PUK15 INPATIENT COST-SAVINGS FROM THE USE OF SUCROFERRIC OXYHYDROXIDE IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING DIALYSIS IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00

  • PNS84 DEMOGRAPHIC FORECASTING WITH UNCERTAINTY OF POPULATION PROJECTION IN CYPRUS: A BAYESIAN PROBABILISTIC POPULATION PROJECTION STUDY

    Nov 1, 2019, 00:00

  • RE2 THEMES IN THE DESIGN OF PHARMACEUTICAL VALUE-BASED CONTRACTS IN THE UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)

    Nov 1, 2019, 00:00

  • PDG27 ARE ACUTE THERAPIES AND CURATIVE DRUGS MORE AFFORDABLE THAN CHRONIC TREATMENTS IN RARE DISEASES? AN ANALYSIS OF THE TOP 20 MOST EXPENSIVE DRUGS IN THE US

    Nov 1, 2019, 00:00

  • PCV45 ATHEROSCLEROSIS: THE COST OF ILLNESS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PCN482 PATIENT-REPORTED OUTCOME MEASURES IN BREAST CANCER: A SYSTEMATIC REVIEW OF EORTC QLQ-C30, FACT-B, AND EORTC QLQ-BR23 DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • PNS169 PERSONAL MEDICAL HEALTH RECORDS REGULATION IN THE UNITED STATED, EUROPEAN UNION AND ISRAEL

    Nov 1, 2019, 00:00

  • PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PNS223 HEALTH-RELATED QUALITY OF LIFE DATA AVAILABILITY IN DRUG APPRAISALS IN FRANCE: WHERE DO WE STAND TODAY?

    Nov 1, 2019, 00:00

  • PCV97 BARRIERS THAT AFFECT ADHERENCE AND PERSISTENCE TO NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILATION (AF) IN TURKEY: A DELPHI STUDY.

    Nov 1, 2019, 00:00

  • PCV124 REPORTING AND QUALITY OF PATIENT PREFERENCE STUDIES: A SYSTEMATIC LITERATURE REVIEW IN THE CARDIOVASCULAR DOMAIN

    Nov 1, 2019, 00:00

  • PCN462 ACCURACY OF RISK SCORING SYSTEM TO DETERMINE DELAYED CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PNS192 ASSESSING FACTORS ASSOCIATED WITH CATASTROPHIC HEALTH CARE PAYMENTS IN A WEST AFRICAN COUNTRY, CÔTE D'IVOIRE

    Nov 1, 2019, 00:00

  • PMD17 RETROSPECTIVE ANALYSIS OF OXIDIZED ZIRCONIUM HIP BEARING SURFACES WHEN A HIP FRACTURE IS PRESENT AT ADMISSION IN THE 90 DAY EPISODE OF CARE

    Nov 1, 2019, 00:00

  • PCV7 ESTIMATION THE PHYSICAL ACTIVITY OF HEART FAILURE PATIENTS BASED ON TELEMETRY DATA

    Nov 1, 2019, 00:00

  • PCV5 3C-HF PROGNOSTIC SCORE TO PREDICT WORSENING CARDIAC FUNCTION AMONG CONGESTIVE HEART FAILURE PATIENTS IN UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • PCN79 A TARGETED LITERATURE REVIEW (TLR) OF THE EPIDEMIOLOGY AND ECONOMIC BURDEN OF ACUTE MYELOID LEUKEMIA (AML)

    Nov 1, 2019, 00:00

  • PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN

    Nov 1, 2019, 00:00

  • PMU129 PERFORMANCE OF A COMPREHENSION QUESTION IN DISCRETE-CHOICE EXPERIMENT SURVEYS (DCE)

    Nov 1, 2019, 00:00

  • Table of Contents

    Nov 1, 2019, 00:00

  • PBI29 LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPIES

    Nov 1, 2019, 00:00

  • PRS46 TREATMENT OF SEVERE ASTHMA IN PORTUGAL: INSIGHTS FROM A PHYSICIANS' SURVEY

    Nov 1, 2019, 00:00

  • PDB84 MANAGEMENT OF PREDIABETES FROM THE PERSPECTIVE OF SPANISH PHYSICIANS AND COMMUNITY PHARMACISTS. DETECTA2 STUDY

    Nov 1, 2019, 00:00

  • PDB116 THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): DESIGN AND BASELINE CHARACTERISTICS

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PCN151 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR WOMEN WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER IN FRANCE

    Nov 1, 2019, 00:00

  • PNS320 ANALYSIS OF MINIMAL IMPORTANT CHANGE THROUGH ITEM RESPONSE THEORY METHODS

    Nov 1, 2019, 00:00

  • PMH53 IMPACT OF COGNITIVE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN CHINESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE PROACT STUDY

    Nov 1, 2019, 00:00

  • PMD55 THE LEARNING CURVE AS A BARRIER IN THE CONDUCT OF RANDOMIZED CONTROLLED TRIALS WITH MEDICAL DEVICES - A LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PNS159 PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY: ISPOR DATABASE SEARCH

    Nov 1, 2019, 00:00

  • PNS391 REAL WORLD USE OF VEHICLES BY OLDER PATIENTS TAKING SOLID ORAL MEDICATIONS: A SURVEY IN THE ONLINE HEALTH NETWORK PATIENTSLIKEME.

    Nov 1, 2019, 00:00

  • PCV142 ESTIMATING THE IMPACT ON RECURRENT HOSPITAL ADMISSIONS AND AMBULATORY VISITS OF PRESCRIBING FERRIC CARBOXYMALTOSE IN IRON DEFICIENCY PATIENTS WITH CHRONIC HEART FAILURE: A RETROSPECTIVE RWE STUDY USING A HOSPITAL REGISTRY IN SPAIN

    Nov 1, 2019, 00:00

  • PMH67 ANALYSIS OF PSYCHOTROPIC MEDICATIONS PRESCRIPTIONS IN TURKEY

    Nov 1, 2019, 00:00

  • AD3 ORAL ANTICOAGULANT PRESCRIPTION TRENDS, PROFILE USE AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00

  • PNS263 THE ROLE OF SURROGATES FOR PATIENT-RELEVANT ENDPOINTS IN THE EARLY BENEFIT ASSESSMENT IN GERMANY

    Nov 1, 2019, 00:00

  • PSY20 COST-EFFECTIVENESS ANALYSIS OF SECUKINUMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PRS62 ASSESSMENT OF PRESCRIPTION PATTERN AND EVALUATION OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2019, 00:00

  • PMU86 A REVIEW OF TOP COUNTRIES CONTRIBUTING TO POSTERS PRESENTED AT ISPOR EUROPE 2018

    Nov 1, 2019, 00:00

  • PIN51 ECONOMIC STUDY OF MEDICO-SURGICAL STRATEGIES IN PATIENTS WITH CHRONIC KNEE OR HIP PROSTHETIC JOINT INFECTION

    Nov 1, 2019, 00:00

  • PCN157 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB + IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN

    Nov 1, 2019, 00:00

  • PRO36 BUDGET IMPACT ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR HEAMOPHILIA A PATIENTS WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN478 HEALTH-RELATED QUALITY OF LIFE OF CANCER PATIENTS IN JAPAN: A POPULATION-BASED NATIONAL HEALTH AND WELLNESS SURVEY STUDY

    Nov 1, 2019, 00:00

  • PCN430 USING BAYESIAN METHODOLOGIES TO INFORM IMMATURE SURVIVAL EXTRAPOLATIONS BASED ON RWD AND EXPERT ELICITATION IN NON-SMALL CELL LUNG CANCER (NSCLC)

    Nov 1, 2019, 00:00

  • PMS3 A COMPARATIVE ANALYSIS OF THE QUALITY OF LIFE OF PATIENTS TREATED WITH MINIMAL INVASIVE ANTERIOR HIP REPLACEMENT SURGERY AND NON-SURGICAL PATIENTS

    Nov 1, 2019, 00:00

  • PMU109 HOW DO NICE EVIDENCE REVIEW GROUPS AND APPRAISAL COMMITTEES PERCEIVE FRACTIONAL POLYNOMIAL METHODOLOGY IN TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PND98 PATTERNS AND PREDICTION FOR COGNITIVE DECLINE IN ALZHEIMER'S PATIENTS AS ASSESSED BY THE MINI-MENTAL STATUS EXAM IN AN AMBULATORY ELECTRONIC MEDICAL RECORD

    Nov 1, 2019, 00:00

  • PNS389 VALIDITY OF THE HUNGARIAN TRANSLATION OF THE CARERQOL-7D INSTRUMENT AMONG INFORMAL CAREGIVERS IN THE HUNGARIAN GENERAL POPULATION

    Nov 1, 2019, 00:00

  • PRO106 A NEW MAJOR MARKET ACCESS CHALLENGE - KEEPING THE ROI WINDOW OPEN?

    Nov 1, 2019, 00:00

  • PCV151 REAL WORLD EVIDENCE OF THE EFFECT OF PERIPHERAL ARTERIAL DISEASE (PAD) ON PATIENT HEALTH OUTCOMES AND COSTS IN AUSTRALIA.

    Nov 1, 2019, 00:00

  • PRS40 CURRENT TREATMENT STATUS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IN JAPAN: A CLAIMS-BASED RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PMH31 COST-EFFECTIVENESS OF GUIDED INTERNET-DELIVERED COGNITIVE BEHAVIORAL THERAPY IN COMPARISON WITH CARE-AS-USUAL FOR PATIENTS WITH INSOMNIA IN GENERAL PRACTICE

    Nov 1, 2019, 00:00

  • PRO112 THE HST TEST: GOOD, BETTER, BEST?

    Nov 1, 2019, 00:00

  • PND74 PREVALENCE OF PROGRESSIVE SUPRANUCLEAR PALSY (PSP) IN EUROPE, JAPAN AND THE USA

    Nov 1, 2019, 00:00

  • PDB63 COST-EFFECTIVENESS OF INSULIN PUMP AND CONTINUES GLUCOSE MONITORING VERSUS MULTIPLE DAILY INJECTIONS AND SELF-MONITORING OF BLOOD GLUCOSE IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • PCN296 OUT WITH THE OLD AND IN WITH THE NEW: THE EVOLUTION OF THE CANCER DRUGS FUND

    Nov 1, 2019, 00:00

  • PCN65 ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN

    Nov 1, 2019, 00:00

  • PMS42 PREVALENCE, PAIN INTENSITY AND DISABILITY OF LOW BACK PAIN AMONG INDIAN POPULATION. A CROSS SECTIONAL STUDY

    Nov 1, 2019, 00:00

  • PDB47 HIPOS-WARD (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - WARD PATIENTS) VS. HIPOS-ER (HYPOGLICEMIA IN PORTUGAL OBSERVATIONAL STUDY - EMERGENCY ROOM) - A COMPARISON OF THE ECONOMIC OUTCOMES

    Nov 1, 2019, 00:00

  • PMH27 SUCCESSFULLY TREATED PATIENTS WITH VORTIOXETINE VERSUS VENLAFAXINE: A SIMPLIFIED COST-EFFECTIVENESS ANALYSIS IN ASIAN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2019, 00:00

  • PCN393 REVIEW AND VALIDATION OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL EXTRAPOLATION IN TECHNOLOGY APPRAISAL (TA) 366 BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00

  • PMH20 COST-EFFECTIVENESS OF INCREASING THE EFFICIENCY OF THE DETOXIFICATION PROCESS PRIOR TO INITIATION OF EXTENDED-RELEASE NALTREXONE FOR THE TREATMENT OF OPIOID USE DISORDER

    Nov 1, 2019, 00:00

  • PCN308 IDENTIFICATION OF VARIABLES THAT MAY INFLUENCE THE RECOMMENDATION INCLUDED IN THE THERAPEUTIC POSITIONING REPORT OF NEW ONCOLOGY PRODUCTS IN SPAIN

    Nov 1, 2019, 00:00

  • PIH57 THE BLEEDING AND PELVIC DISCOMFORT SCALE: MEASURING PATIENT-REPORTED SYMPTOMS IN UTERINE FIBROIDS

    Nov 1, 2019, 00:00

  • PND49 OUT-OF-POCKET EXPENSES IN MIGRAINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • Surgery - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO138 PRODUCTIVITY LOSSES IN PEOPLE WITH CHARCOT-MARIE-TOOTH DISEASE IN THE EU AND US: INTERIM RESULTS FROM AN INTERNATIONAL DIGITAL REAL-WORLD EVIDENCE STUDY

    Nov 1, 2019, 00:00

  • Treatment Patterns Guidelines Studies

    Nov 1, 2019, 00:00

  • NO Specific Disease - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PIH47 COMPARISON OF CAESAREAN SECTION RATES IN GEOGRAPHICAL AREAS OF WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • PRO51 COST-EFFECTIVENESS AND BUDGET IMPACT OF ONASEMNOGENE ABEPARVOVEC FOR SPINAL MUSCULAR ATROPHY TYPE 1: POST-HOC ANALYSIS OF A MODEL DEVELOPED BY ICER

    Nov 1, 2019, 00:00

  • PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE

    Nov 1, 2019, 00:00

  • PCN208 COST-EFFECTIVENESS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH INVOLVEMENT OF LYMPH NODES OR METASTATIC DISEASE WHO HAVE UNDERGONE COMPLETE RESECTION: AN ANALYSIS FROM A SWISS HEALTHCARE SYSTEM PERSPECTIVE

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Patient-Centered Research

    Nov 1, 2019, 00:00

  • PMH61 NEUROLEPTIC THERAPY COMPLIANCE DIFFERS AMONG PATIENTS TREATED BY DIFFERENT PSYCHIATRISTS

    Nov 1, 2019, 00:00

  • PIH54 HEALTH RELATED QUALITY OF LIFE OF PRE-ADOLESCENT DEAF CHILDREN WITH COCHLEAR IMPLANTS: A CONCEPTUAL DISEASE MODEL

    Nov 1, 2019, 00:00

  • PMU14 NON-MEDICAL SWITCHING AT THE HOSPITAL: A SYSTEMATIC REVIEW ON THERAPEUTIC CLASSES AND PATHOLOGIES THAT ARE APPROPRIATE TO ACHIEVE SAVINGS

    Nov 1, 2019, 00:00

  • PNS205 SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS

    Nov 1, 2019, 00:00

  • PCN385 PAY-FOR-PERFORMANCE IN ONCOLOGY: A SUCCESSFUL STORY FROM BULGARIA

    Nov 1, 2019, 00:00

  • PCN100 HEALTH-ECONOMIC EVALUATION OF LUNG CANCER DRUGS: DO S AND DON TS IN FRANCE

    Nov 1, 2019, 00:00

  • PND29 THE COST OF ACHIEVING NEDA WHILE USING TWO ALTERNATIVE FORMULATIONS OF INTERFERON BETA-1A FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN PORTUGAL: LET'S LOOK AT EVIDENCE

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PRO32 DE NOVO ECONOMIC MODEL TO ASSESS THE IMPACT OF SIZE AND DURABILITY OF EFFECT OF CURATIVE CELL AND GENE THERAPIES IN TREATMENT OF PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA (CDA)

    Nov 1, 2019, 00:00

  • PRO146 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY/ACTIVITY IMPAIRMENT IN PATIENTS WITH TRANSFUSION DEPENDENT B-THALASSAEMIA IN THE UK NHS: DATA FROM A UK MULTICENTRE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PBI18 ESTIMATION OF THE HEALTHCARE RESOURCE UTILIZATION (HCRU) COSTS IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA RECEIVING TISAGENLECLEUCEL: A MICRO-COSTING STUDY IN THE UK AND FRANCE

    Nov 1, 2019, 00:00

  • PMU24 ECONOMIC EVALUATION OF BIOCELLULOSE WOUND DRESSINGS FOR THE MANAGEMENT OF CHRONIC LEG ULCERS IN CANADA

    Nov 1, 2019, 00:00

  • PNS404 USING DATA WAREHOUSES TO OPTIMIZE HEALTHCARE DECISION MAKING

    Nov 1, 2019, 00:00

  • Multiple Diseases - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PNS228 TIME FOR REIMBURSEMENT AND PRICING FOR DRUGS DEPENDING ON THE EARLY ACCESS STATUS IN FRANCE (WITH OR WITHOUT ATU)

    Nov 1, 2019, 00:00

  • PRO18 BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE

    Nov 1, 2019, 00:00

  • PCN256 RESULTS FROM THE CALIBRATION OF A MICROSIMULATION COLON CANCER SCREENING FRENCH MODEL

    Nov 1, 2019, 00:00

  • PCN477 APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY: RESULTS FROM A TOBIT REGRESSION

    Nov 1, 2019, 00:00

  • PIN33 COST-EFFECTIVENESS OF CURRENT PNEUMOCOCCAL VACCINES IN OLDER ADULTS IN EUROPEAN SETTINGS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS

    Nov 1, 2019, 00:00

  • PNS261 THE HEALTH ECONOMIC DOMAIN WITHIN HEALTH TECHNOLOGY ASSESSMENTS IN GERMANY — FIRST RESULTS AND ENSUING CONSEQUENCES OF THEMENCHECK MEDIZIN

    Nov 1, 2019, 00:00

  • PCN325 REAL-WORLD DATA DESCRIBING THE ROLE OF CHEMOTHERAPY IN THE TREATMENT OF HR+/HER2- MBC PATIENTS: DIVERGENCE FROM EVIDENCE-BASED MEDICINE

    Nov 1, 2019, 00:00

  • PNS208 VALUE AND HEALTH TECHNOLOGY ASSESSMENT: TRANSPARENCY IN USE OF PEER-REVIEWED PUBLICATIONS

    Nov 1, 2019, 00:00

  • Respiratory-Related Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PSY13 BUDGET IMPACT ANALYSIS OF TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN ADULT PATIENTS WITH BARICITINIB IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PDB83 ANALYSIS OF PRESCRIPTION RATES OF INSULIN GLARGINE (IG), PER PRODUCT AND PRESENTATION TYPE, BY GENERAL PRACTITIONERS (GP) IN ENGLAND AND ITS ASSOCIATION WITH HEALTH DETERMINANTS (2013-2018)

    Nov 1, 2019, 00:00

  • PCV110 COST-EFFECTIVENESS OF SUTURELESS AORTIC VALVE REPLACEMENT VERSUS CONVENTIONAL AORTIC VALVE REPLACEMENT AND TRANSCATHETER AORTIC VALVE IMPLANTATION IN BRAZIL

    Nov 1, 2019, 00:00

  • PNS67 WELLBEING VALUATION METHOD ON DETERMINING MONETARY VALUE OF WELFARE LOSS DUE TO HEALTHCARE ACCESS BARRIERS

    Nov 1, 2019, 00:00

  • PNS123 IMPLEMENTATION OF UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Nov 1, 2019, 00:00

  • PRO4 IMPACT OF ENZYME REPLACEMENT THERAPY ON THE RISK OF DEVELOPING GAUCHER DISEASE-RELATED COMPLICATIONS

    Nov 1, 2019, 00:00

  • SP4 EXPLORING HETEROGENEITY IN PREFERENCES FOR ATTRIBUTES OF PHARMACEUTICAL TREATMENTS FOR OSTEOARTHRITIS AND CHRONIC LOW BACK PAIN IN THE UNITED KINGDOM: A LATENT CLASS APPROACH

    Nov 1, 2019, 00:00

  • PMU23 COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS DISEASE. COEPSO STUDY

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN351 COMPARATIVE STUDY OF PFS AS PRIMARY ENDPOINT IN EUROPEAN HTA (FRANCE AND GERMANY)

    Nov 1, 2019, 00:00

  • CP4 META-ANALYSIS POWERED BY ARTIFICIAL INTELLIGENCE

    Nov 1, 2019, 00:00

  • Cancer - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PCV28 CHARACTERIZATION OF COSTS AND PATIENTS WITH INCIDENT HEART FAILURE (HF) INCURRING THE HIGHEST HEALTHCARE COSTS FROM SECONDARY CARE: A RETROSPECTIVE, POPULATION-BASED COHORT STUDY IN SWEDEN

    Nov 1, 2019, 00:00

  • PIN112 DISPARITIES AND SIMILARITIES IN THE INFLUENZA VACCINATION RECOMMENDATIONS ACROSS UNITED STATES AND EUROPE

    Nov 1, 2019, 00:00

  • PNS373 IDENTIFICATION AND RECOMMENDATIONS OF READABILITY TESTS FOR THE EVALUATION OF CLINICAL OUTCOME ASSESSMENTS

    Nov 1, 2019, 00:00

  • PSS8 EXTENDED LOADING DOSE OF ANTI-VEGF TREATMENT IN DIABETIC MACULAR EDEMA PATIENTS: A COST-CONSEQUENCE ANALYSIS

    Nov 1, 2019, 00:00

  • PMS7 EFFICACY EXAMINATION OF PILATES TRAINING AMONG HEALTHY WOMEN ON THE CHANGE OF TRUNK STATE, POSTURE, LUMBAR MOTOR CONTROL ABILITY AND BALANCE

    Nov 1, 2019, 00:00

  • PND42 THE PRODUCTIVITY IMPACT OF EXCEEDING THE LEGAL TIME FOR PRICING AND REIMBURSEMENT DECISION OF ERENUMAB IN THE TREATMENT OF MIGRAINE IN PORTUGAL

    Nov 1, 2019, 00:00

  • PNS407 PATIENT SELECTION PROCESS IN REAL-WORLD DATA FROM ELECTRONIC HEALTH RECORDS - SUGGESTED STANDARDISED PROCESS FOR SELECTING PATIENTS

    Nov 1, 2019, 00:00

  • RW3 HUMAN PAPILLOMA VIRUS IN ITALY: RETROSPECTIVE COHORT ANALYSIS AND VACCINATION EFFECT FROM REAL-WORLD DATA

    Nov 1, 2019, 00:00

  • PCV137 ADHERENCE TO ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS OF A MULTI-COUNTRY STUDY

    Nov 1, 2019, 00:00

  • PNS175 THE IMPACT OF RE-PRICING POLICY ON THE PRICE OF ANTI-CANCER DRUGS FROM 2007 TO 2017 IN SOUTH KOREA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PSY29 EARLY-STAGE MYCOSIS FUNGOIDES: INCIDENCE AND DIFFERENTIAL SURVIVAL

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • Urinary/Kidney Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN354 RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS

    Nov 1, 2019, 00:00

  • Systemic Disorders/Conditions - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • PIN142 IMPACT OF ADHERENCE ON VIRAL SUPPRESSION AND DETERMINANTS OF ADHERENCE IN PATIENTS WITH HIV

    Nov 1, 2019, 00:00

  • PNS251 FACTORS ASSOCIATED WITH THE OUTCOMES OF RAPID REVIEWS SUBMITTED TO THE NCPE

    Nov 1, 2019, 00:00

  • PCN132 SYSTEMATIC REVIEW OF ECONOMIC BURDEN IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS

    Nov 1, 2019, 00:00

  • PMD48 OPPORTUNITIES AND CHALLENGES FOR NOVEL MEDICAL DEVICES LAUNCHING IN EUROPE IN THE HOSPITAL SETTING

    Nov 1, 2019, 00:00

  • PBI69 INSIGHTS INTO FUTURE AUTOIMMUNE PRICING DYNAMICS IN EU5 THE US, USING LEARNINGS FROM RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PUK17 EARLY CONVERSION FROM INTRAVENOUS TO ORAL ANTIBIOTICS: ASSESSMENT AND EVALUATION OF ECONOMIC OUTCOMES IN HOSPITALIZED PATIENTS

    Nov 1, 2019, 00:00

  • PRS70 APPLYING DIFFERENT MEASURES TO ASSESS PATIENTS' NON-ADHERENCE: RESULTS OF A LINKED DATA STUDY OF PATIENTS WITH ASTHMA IN GERMANY

    Nov 1, 2019, 00:00

  • PBI59 THE REIMBURSEMENT STATUS OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Nov 1, 2019, 00:00

  • Multiple Diseases - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PCN31 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HCRU) IN SECOND-LINE (2L) ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN ASIAN VERSUS WESTERN COUNTRIES

    Nov 1, 2019, 00:00

  • PCN53 CHECKPOINT INHIBITOR USE AND THE OCCURRENCE OF INSULIN-DEPENDENT OR DRUG-INDUCED DIABETES: WHAT CAN WE LEARN FROM REAL WORLD DATA?

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Real World Data Information Systems

    Nov 1, 2019, 00:00

  • PIN52 STUDIES REPORTING COSTS ASSOCIATED WITH INVASIVE MENINGOCOCCAL DISEASE IN EU-27: METHODOLOGY AND OUTCOMES

    Nov 1, 2019, 00:00

  • PNS405 DERIVING DATA FOR COST-EFFECTIVENESS MODELS FROM THE FRENCH SNDS DATABASE: A FEASIBILITY ASSESSMENT

    Nov 1, 2019, 00:00

  • PRO151 PROJECT HERCULES: A MODIFIED DELPHI SURVEY TO INFORM A BURDEN-OF-ILLNESS STUDY IN DUCHENNE MUSCULAR DYSTROPHY

    Nov 1, 2019, 00:00

  • PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE

    Nov 1, 2019, 00:00

  • PNS237 CLINICAL OUTCOME ASSESSMENTS AS A CONDITION IN HTA RECOMMENDATIONS: THE CANADIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN112 RESEARCH TREND OF THE PHARMACOECONOMIC STUDIES OF SMALL-MOLECULE PROTEIN KINASE INHIBITORS IN CHINA

    Nov 1, 2019, 00:00

  • PCN513 RETROSPECTIVE STUDY DESCRIBING THE DEMOGRAPHIC CHARACTERISTICS, INCIDENCE, TREATMENT, COMORBIDITIES, MORTALITY, AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH MYELOFIBROSIS AND POLYCYTHEMIA VERA IN SWEDEN

    Nov 1, 2019, 00:00

  • PRS9 HOW CLINICAL TRIALS INCORPORATED OUTCOMES RELEVANT FOR HEALTH ECONOMIC EVALUATION: AN EVIDENCE GAP ANALYSIS BASED ON SYSTEMATIC REVIEW OF CLINICAL TRIALS FOR MODERATE-TO-SEVERE ASTHMA IN JAPAN

    Nov 1, 2019, 00:00

  • PRO111 REIMBURSEMENT OF ULTRA-ORPHAN MEDICINES: A NEW BEST-PRACTICE FRAMEWORK?

    Nov 1, 2019, 00:00

  • PCN54 EFFICACY AND SAFETY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED, ADVANCED STAGE MYCOSIS FUNGOIDES AND SÉZARY SYNDROME PATIENTS: A POST-HOC ANALYSIS OF THE MAVORIC STUDY

    Nov 1, 2019, 00:00

  • PNS256 PUBLIC VIEWS ON PRIORITY-SETTING CRITERIA FOR LIMITED HEALTHCARE RESOURCE

    Nov 1, 2019, 00:00

  • PRO108 ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS

    Nov 1, 2019, 00:00

  • PNS305 PATIENT-LEVEL SIMULATION MODELS: THE POWER OF PARALLEL WORLDS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Conceptual Papers (CP)

    Nov 1, 2019, 00:00

  • PMD25 COMPARING ECONOMIC IMPACT OF CENTRIFUGAL AND MEMBRANE THERAPEUTIC PLASMA EXCHANGE IN A SINGLE INSTITUTION IN THAILAND

    Nov 1, 2019, 00:00

  • PIN10 GROWTH FACTORS AND THEIR IMPACT ON HEALTHCARE UTILIZATION AND COST IN CACHECTIC HIV PATIENTS

    Nov 1, 2019, 00:00

  • PMU98 UTILITY OF EARLY ACCESS TO MEDICINES SCHEME DATA FOR NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • PNS210 NATIONAL HEALTH TECHNOLOGY SYSTEM (SINATS) IN PORTUGAL: 4-YEAR LANDMARK ANALYSIS

    Nov 1, 2019, 00:00

  • PCN369 WHAT IS THE REGULATORY AND HTA LANDSCAPE OF NON-SMALL CELL LUNG CANCER DRUGS ACROSS THE EU5 COUNTRIES?

    Nov 1, 2019, 00:00

  • PNS219 TARGETED LITERATURE REVIEW AND PAYERS' PERSPECTIVES ON THE CURRENT PROGRESS OF HTA SYSTEM IMPLEMENTATION IN THE MENA REGION

    Nov 1, 2019, 00:00

  • PNS46 POISSON REPRESENTATION OF MARKOV COHORT STATE-TRANSITION MODELS

    Nov 1, 2019, 00:00

  • PRO98 ULTRA-ORPHAN MEDICINAL PRODUCTS ASSESSMENT: COMPARISON OF THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) HTA FRAMEWORKS

    Nov 1, 2019, 00:00

  • ON2 VARIATION IN METHODOLOGICAL APPROACH TO PRODUCTIVITY COST VALUATION: DISTRIBUTIONAL EFFECTS IN THE CASE OF PROSTATE CANCER

    Nov 1, 2019, 00:00

  • PDG59 THE IMPACT OF TEMPORARY AUTHORIZATION USE (ATU) DOSSIER IN FRANCE SINCE THE CREATION OF FFIP (PHARMACEUTICAL INNOVATION FINANCING FUND) IN 2017

    Nov 1, 2019, 00:00

  • PRO80 COMPARISON OF EARLY ACCESS PROGRAMMES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES

    Nov 1, 2019, 00:00

  • PNS282 ANALYSIS OF METHODOLOGICAL LIMITATIONS RAISED BY THE FRENCH HEALTH TECHNOLOGY ASSESSMENT ON PUBLISHED EFFICIENCY OPINIONS FROM FEBRUARY 2014 TO MAY 2019

    Nov 1, 2019, 00:00

  • PDB28 A HEALTH ECONOMIC AND DECISION MODELLING ANALYSIS PLAN FOR AN INTEGRATED DATABASE OF OVER 100 CLINICAL TRIALS MEASURING HYPOGLYCAEMIC ATTACKS FOR PEOPLE WITH DIABETES: A HEDMAP FOR HYPORESOLVE

    Nov 1, 2019, 00:00

  • PNS128 READY FOR PRIME TIME? HAVE EMA PRIME DESIGNATIONS SUPPORTED ACCELERATED REGULATORY APPROVAL AND PATIENT ACCESS?

    Nov 1, 2019, 00:00

  • PND86 COST-UTILITY ANALYSIS OF DELTA-9-TETRAHIDROCANNABINOL AND CANNABIDIOL OROMUCOSAL SPRAY

    Nov 1, 2019, 00:00

  • PNS339 BAYESIAN NETWORK META-ANALYSES WHERE INFORMATIVE PRIORS WERE USED FOR THE BETWEEN-STUDY HETEROGENEITY; A PRAGMATIC REVIEW

    Nov 1, 2019, 00:00

  • PNS310 TRENDS IN CLINICAL TRIALS FOR DIGITAL HEALTH TECHNOLOGIES

    Nov 1, 2019, 00:00

  • PMU67 PERFORMACE-BASED SCHEMES IN ITALY: IMPACT OF THEIR APPLICATION IN THE LAST 5 YEARS (2013-2017)

    Nov 1, 2019, 00:00

  • PCN8 EXAMINATION OF FACTORS INFLUENCING THE OCCURRENCE OF THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS (MPN) BASED ON HUNGARIAN NATIONAL REGISTRY DATA

    Nov 1, 2019, 00:00

  • PMU124 ATTENDING PHYSICIAN MODELS OF CARE AND PATIENT OUTCOMES

    Nov 1, 2019, 00:00

  • PIH32 EPIDEMIOLOGIC FACTORS PREDISPOSING TO PEDIATRIC OBESITY: A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2019, 00:00

  • Alternative Medicine Information Systems

    Nov 1, 2019, 00:00

  • PNS333 EXTRAPOLATING SURVIVAL BY ASSUMING PROPORTIONAL HAZARDS BETWEEN GENERAL POPULATION MORTALITY AND DISEASE SPECIFIC MORTALITY

    Nov 1, 2019, 00:00

  • PNS160 ESTIMATING THE MARKET VALUE OF PERSONAL HEALTH RECORDS: THE CASE OF INDIVIDUAL DATA OWNERSHIP

    Nov 1, 2019, 00:00

  • PCN282 ASSESSING THE EVOLUTION OF THE PRICING AND ACCESS LANDSCAPE FOR CELL AND GENE THERAPIES IN THE US AND EU3 THROUGH A WEB-BASED PORTAL TO ENGAGE PAYERS

    Nov 1, 2019, 00:00

  • PMD2 IMPLANTABLE CARDIAC MONITORS (BIOMONITOR 2-AF, CONFIRM RX INSERTABLE CARDIAC MONITOR AND REVEAL LINQ INSERTABLE CARDIAC MONITORING SYSTEM) TO DETECT ATRIAL FIBRILLATION AFTER CRYPTOGENIC STROKE: A SYSTEMATIC REVIEW

    Nov 1, 2019, 00:00

  • PDB19 THE BIAS OF IGNORING CARDIOPROTECTIVE EFFECTS IN COST-EFFECTIVENESS ANALYSIS IN DIABETES

    Nov 1, 2019, 00:00

  • PCV85 THE LONG-TERM EFFECT OF PARTICULATE MATTER(PM2.5, PM10) ON INCIDENCE AND MORTALITY OF MYOCARDIAL INFARCTION(MI): A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00

  • PND61 DIRECT AND INDIRECT COSTS OF MIGRAINE IN HEADACHE SPECIALIST CENTERS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PMS75 BURDEN OF DISEASE AND UNMET NEEDS OF KNEE OSTEOARTHRITIS IN COLOMBIA

    Nov 1, 2019, 00:00

  • PRS6 HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH SYMPTOMATIC COPD AND EXACERBATIONS IN CHILE: SUB-ANALYSIS OF THE IMPACT TRIAL

    Nov 1, 2019, 00:00

  • PRO119 A NOVEL MAPPING APPROACH FOR ESTIMATING UTILITIES IN NON-DYSTROPHIC MYOTONIA

    Nov 1, 2019, 00:00

  • PNS329 ESTIMATION OF A DUTCH TARIFF FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT FOUR-LEVEL SELF-COMPLETION TOOL (ASCOT-SCT4)

    Nov 1, 2019, 00:00

  • PSY47 PATIENT-REPORTED OUTCOMES IN CHINESE ADULT RHEUMATOID ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2019, 00:00

  • PSU42 PHARMACOVIGILANCE OF ANESTHETICS IN THE DEPARTMENT OF GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PCV69 COST EFFECTIVENESS ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN STEMI PATIENTS FROM NATIONAL HEART INSTITUTE PERSPECTIVE IN EGYPT

    Nov 1, 2019, 00:00

  • PNS52 ASSESSMENT OF THE IMPACT OF THE LEVEL OF ASMR ON THE DRUG'S PRICE AND ITS NEGOTIATION TIME WITH THE HEALTH AUTHORITIES IN TREATMENTS THAT BENEFITED FROM THE FRENCH EARLY ACCESS PROGRAM

    Nov 1, 2019, 00:00

  • PCN431 EFFICACY PREDICTION IN PHASE I ONCOLOGY CLINICAL TRIALS USING DEEP LEARNING

    Nov 1, 2019, 00:00

  • AD2 DYNAMICS OF SWITCHING, ADHERENCE, AND PERSISTENCE OF SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS USE: AN AUSTRALIAN PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN42 CABOZANTINIB VERSUS STANDARD-OF-CARE COMPARATORS: A NETWORK META-ANALYSIS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA

    Nov 1, 2019, 00:00

  • PCN377 WHERE DO WE GO WITH WHOLE GENOME SEQUENCING IN ONCOLOGY? USING SCENARIO DRAFTING TO EXPLORE FUTURE DEVELOPMENTS

    Nov 1, 2019, 00:00

  • PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE

    Nov 1, 2019, 00:00

  • PNS216 NICE HIGHLY SPECIALISED TECHNOLOGY ASSESSMENT: HOW ARE SELECTION CRITERIA APPLIED IN PRACTICE?

    Nov 1, 2019, 00:00

  • PIH20 A TARGETED LITERATURE REVIEW OF THE ECONOMIC BURDEN ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME

    Nov 1, 2019, 00:00

  • PMD11 MEASURING THE ECONOMIC IMPACT OF THERAPEUTIC PLASMA EXCHANGE: A SINGLE INSTITUTION STUDY IN XIAMEN, CHINA

    Nov 1, 2019, 00:00

  • PMH26 MODEL DEVELOPMENT FOR ASSESSING COST-EFFECTIVENESS AND PREPARE REIMBURSEMENT DOSSIER OF RTMS IN PATIENT POPULATION WITH TREATMENT-RESISTANT DEPRESSION IN HUNGARY

    Nov 1, 2019, 00:00

  • HT2 IS THERE POTENTIAL FOR JOINT HEALTH TECHNOLOGY ASSESSMENT (HTA) IN EUROPE? AN EVALUATION OF EUNETHTA JOINT CLINICAL ASSESSMENTS VS. NATIONAL APPRAISALS IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PIH12 VARIATIONS IN HEALTH INSURANCE AFFECT HEALTHCARE UTILIZATION IN CHILDREN WITH CROHNS DISEASE IN THE USA

    Nov 1, 2019, 00:00

  • PCN490 MAKING OUTCOME-BASED PAYMENT A REALITY IN THE NATIONAL HEALTH SERVICE FOR ENGLAND

    Nov 1, 2019, 00:00

  • PNS29 HEALTH RESEARCH AND BIG DATA IN UKRAINE: PERSPECTIVES AND CONCERNS

    Nov 1, 2019, 00:00

  • PMH60 ASSESSMENT OF THE INTERNAL CONSISTENCY AND CONCURRENT VALIDITY OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN AN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER POPULATION-BASED SAMPLE

    Nov 1, 2019, 00:00

  • PNS260 INCLUSION OF NEW STRATEGIES IN THE UK'S CANCER DRUG FUND: WHAT WAS DECIDED IN FRANCE?

    Nov 1, 2019, 00:00

  • RE4 IS MARKET ACCESS FOR ONCOLOGY TREATMENTS EASIER IN ENGLAND THAN FOR NON-ONCOLOGY TREATMENTS? AN ANALYSIS OF NICE SINGLE TECHNOLOGY APPRAISALS FROM 2017-2019

    Nov 1, 2019, 00:00

  • PCN150 IMPACT OF USING IMMATURE SURVIVAL DATA ON NICE DECISION-MAKING

    Nov 1, 2019, 00:00

  • PMU107 INSIGHTS INTO REIMBURSEMENT RATES AND TIMELINES FOR ORPHAN DRUGS IN IRELAND

    Nov 1, 2019, 00:00

  • PDB22 BUDGET IMPACT ANALYSIS OF THE SELF-MONITORING OF BLOOD GLUCOSE DEVICES FOR TYPE 1 AND TYPE 2 DIABETES MELLITUS IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PMU3 RISK FACTORS FOR ADVERSE DRUG REACTIONS IN PATIENTS UNDERGOING GENERAL SURGERY: A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2019, 00:00

  • PDB4 A COST OFFSET ANALYSIS (COA) COMPARING REAL-TIME CONTINUOUS GLUCOSE MONITORING (RT-CGM) WITH INTERMITTENT SCANNING CONTINUOUS GLUCOSE MONITORING (IS-CGM) IN TYPE 1 DIABETES (T1D) SUBJECTS WITH IMPAIRED HYPOGLYCEMIA AWARENESS IN EIGHT C ...

    Nov 1, 2019, 00:00

  • PCN456 REAL WORLD HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR FIRST LINE RECURRENT/ METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) PATIENTS

    Nov 1, 2019, 00:00

  • PNS220 SUBMISSION PROCESS AND REQUIREMENTS OF NORDIC HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES FOR HOSPITAL DRUGS: IMPLICATIONS FOR MARKET ACCESS STRATEGY

    Nov 1, 2019, 00:00

  • PMD32 STRUCTURE AND EVOLUTION OF THE FRENCH POSITIVE REIMBURSEMENT LIST FOR MEDICAL DEVICES

    Nov 1, 2019, 00:00

  • PND57 INFORMAL CARE COST IN NEUROLOGIC DISORDERS WITH THE CONTINGENT VALUATION METHOD

    Nov 1, 2019, 00:00

  • PRO25 COST OF HEALTHCARE RESOURCE UTILIZATION IN INTERSTITIAL LUNG DISEASES IN GERMANY IN 2017

    Nov 1, 2019, 00:00

  • PCV91 CHANGES IN THE MORTALITY RELATED TO ISCHAEMIC HEART DISEASE IN PEOPLE ABOVE 65 YEARS BETWEEN 1990-2015 IN WHO EUROPEAN REGION

    Nov 1, 2019, 00:00

  • PND31 COST-EFFECTIVENESS ANALYSIS OF 5% LIDOCAINE PLASTER COMPARED TO PREGABALIN IN PATIENTS WITH POSTHERPETIC NEURALGIA IN CHINA

    Nov 1, 2019, 00:00

  • PRO34 COST-EFFECTIVENESS OF EMICIZUMAB VERSUS BY-PASSING AGENTS IN PATIENTS WITH HAEMOPHILIA A AND FVIII INHIBITORS IN FRANCE.

    Nov 1, 2019, 00:00

  • PDG52 CONSISTENCY OF NEW DRUG PRICING IN KOREA: BRIDGING VARIATIONS AMONG PERSONNEL IN PRICE NEGOTIATIONS

    Nov 1, 2019, 00:00

  • PRO41 COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.

    Nov 1, 2019, 00:00

  • PDG35 RACE, SLEEP TESTING, AND TREATMENT DIFFERENCES BETWEEN NARCOLEPTIC PEDIATRIC POPULATIONS WITH AND WITHOUT CATAPLEXY: A FEDERATED ELECTRONIC MEDICAL RECORD (EMR) NETWORK ANALYSIS

    Nov 1, 2019, 00:00

  • PIN40 COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA

    Nov 1, 2019, 00:00

  • ON7 TIME-TO-TREATMENT DISCONTINUATION (TTD) AS A PRAGMATIC PREDICTOR OF OVERALL SURVIVAL (OS) IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) - REAL-WORLD PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN473 PREFERENCES FOR CHEMOTHERAPY SIDE EFFECTS IN SAUDI BREAST CANCER PATIENTS: A DISCRETE-CHOICE EXPERIMENT

    Nov 1, 2019, 00:00

  • CE2 EFFICACY OF BRODALUMAB AND GUSELKUMAB IN PATIENTS WITH PLAQUE PSORIASIS WHO ARE INADEQUATE RESPONDERS TO USTEKINUMAB: A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)

    Nov 1, 2019, 00:00

  • PMH28 ASSESSING THE LIFE-CYCLE VALUE ADDED OF SECOND-GENERATION ANTIPSYCHOTICS IN SWEDEN AND THE UK: THE CASE OF RISPERIDONE

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00

  • PMS35 EVIDENCE MAP OF ECONOMIC EVALUATIONS IN RHEUMATOID ARTHRITIS

    Nov 1, 2019, 00:00

  • PIN61 ANALYSIS ON DIRECT MEDICAL EXPENSES OF PATIENTS WITH PULMONARY TUBERCULOSIS IN CHINA: BASED ON THE CASE OF 17,000 PATIENTS IN WUHAN

    Nov 1, 2019, 00:00

  • PCN326 ASSESSMENT OF THE ONCOLOGICAL OFFER AMONG ITALIAN REGIONS: A PATIENT-CENTERED ANALYSIS

    Nov 1, 2019, 00:00

  • PMD42 THE DIRECT COSTS ASSOCIATED WITH POSTERIOR CAPSULE OPACIFICATION IN THE NETHERLANDS: A PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCV53 COST-EFFECTIVENESS OF THE CNIC POLYPILL - FIXED DOSE COMBINATION OF ACETYLSALICYLIC ACID, RAMIPRIL AND ATORVASTATIN - FOR THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN GREECE

    Nov 1, 2019, 00:00

  • PMU59 ANALYSIS OF THE EVOLUTION IN THE ACCESS TO MEDICINES IN ITALY IN THE LAST 5 YEARS (2014-2018)

    Nov 1, 2019, 00:00

  • PRO72 MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT

    Nov 1, 2019, 00:00

  • Neurological Disorders Studies

    Nov 1, 2019, 00:00

  • PSY23 DIRECT COSTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN ALBERTA IN REAL WORLD

    Nov 1, 2019, 00:00

  • PCN386 GERMAN BENEFIT ASSESSMENT IN THE FIELD OF ONCOLOGY: FACTORS INFLUENCING THE BENEFIT RATING IN ADDITION TO COMPLYING WITH THE APPROPRIATE COMPARATOR

    Nov 1, 2019, 00:00

  • PNS72 EVALUATION OF MEDICAL TECHNOLOGIES WITH UNCERTAIN BENEFITS

    Nov 1, 2019, 00:00

  • MT2 UNDERSTANDING POTENTIAL CAPACITY CONSTRAINTS RESTRICTING TIME-TO-DIAGNOSIS IN A MULTI-DISCIPLINARY DIAGNOSTIC CENTRE (MDC) FOR PEOPLE WITH NON-SPECIFIC SYMPTOMS OF CANCER: A DISCRETE EVENT SIMULATION

    Nov 1, 2019, 00:00

  • PCN374 BETTER LATE THAN NEVER: THE DYNAMICS OF NICE DECISION-MAKING UNDER THE NEW MODEL OF THE CDF

    Nov 1, 2019, 00:00

  • PCN102 DATA INTELLIGENCE FOR THE EVALUATION OF NEW TREATMENTS FOR BREAST CANCER: QUEST FOR A BETTER METHOD TO ESTIMATE AFFORDABILITY IN SCOTLAND

    Nov 1, 2019, 00:00

  • PNS377 BARRIERS AND ENABLERS TO PATIENT ENGAGEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS: AN IRISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PCN291 ADEQUATE DATA SOURCES TO FACILITATE INNOVATIVE PRICING SOLUTIONS FOR PHARMACEUTICALS WITH MULTIPLE INDICATIONS IN GERMANY

    Nov 1, 2019, 00:00

  • Stated Preference Patient Satisfaction Research

    Nov 1, 2019, 00:00

  • Drugs Regulatory

    Nov 1, 2019, 00:00

  • PNS328 REAL OPTIONS ANALYSIS FOR MORE OPTIMALLY INFORMED REIMBURSEMENT DECISIONS

    Nov 1, 2019, 00:00

  • PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL

    Nov 1, 2019, 00:00

  • PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION?

    Nov 1, 2019, 00:00

  • PDG9 TRANSCON TECHNOLOGY: SOLVING UNMET NEED. VALIDATION IN PEDIATRIC GROWTH HORMONE DEFICIENCY

    Nov 1, 2019, 00:00

  • Mental Health - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMH58 COMPARATIVE ANALYSIS BETWEEN THE MICROSTRUCTURE NETWORK MANAGEMENT AND THE CONVENTIONAL MEDICAL OF PERSONS WITH ADDICTION IN FRANCE

    Nov 1, 2019, 00:00

  • Biologics/Biosimilars/Regenerative Medicine - Economic Evaluation

    Nov 1, 2019, 00:00

  • PNS214 STEPS OF THE CREATION OF A HTA-INFORMED HEALTH CARE DECISION-MAKING ECOSYSTEM IN UKRAINE

    Nov 1, 2019, 00:00

  • Medical Devices - Economic Evaluation

    Nov 1, 2019, 00:00

  • PMU88 WHAT IS THE ROLE OF THE COMPANY EVIDENCE SUBMISSION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) MULTIPLE TECHNOLOGY APPRAISALS?

    Nov 1, 2019, 00:00

  • PGI2 EVALUATION OF PATIENTS DEPRESCRIBED OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS USING KWAS QUESTIONNAIRE

    Nov 1, 2019, 00:00

  • PCN265 TARGETED REVIEW OF ADVERSE EVENTS ASSOCIATED WITH TREATMENTS FOR STAGE 3 AND 4 MELANOMA

    Nov 1, 2019, 00:00

  • RARE Statistical Research

    Nov 1, 2019, 00:00

  • PDG15 EFFICIENCY AND PRODUCTION OF THE AREA OF PREPARATION OF INTRAVENOUS ADMIXTURES AND STERILE MEDICATIONS

    Nov 1, 2019, 00:00

  • PCV58 TOTAL COSTS OF TREATMENT OF PATIENTS SUFFERING FROM VENOUS THROMBOEMBOLISM - IMPLICATIONS OF DIFFERENT COST PERSPECTIVES

    Nov 1, 2019, 00:00

  • PBI22 COST-EFFECTIVENESS OF SECUKINUMAB VERSUS OTHER BIOLOGICS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A SPANISH PERSPECTIVE

    Nov 1, 2019, 00:00

  • PMU37 NEWLY DIAGNOSED NONALCOHOLIC FATTY LIVER DISEASE AFTER BARIATRIC SURGERY: A STUDY OF ELECTRONIC MEDICAL RECORD DATA

    Nov 1, 2019, 00:00

  • HT3 WHAT INFLUENCES THE PROBABILITY TO BE SUCCESSFUL IN AN ONCOLOGY HTA? AN ANALYSIS OF ONCOLOGY HTA DECISIONS IN GERMANY, SPAIN AND THE UK

    Nov 1, 2019, 00:00

  • PBI57 PAYER AND PHYSICIAN DYNAMICS SURROUNDING BIOSIMILAR ACCESS IN THE EU

    Nov 1, 2019, 00:00

  • PGI4 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY AND SAFETY OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

    Nov 1, 2019, 00:00

  • PRS31 THE IMPACT TRIAL: COST-EFFECTIVENESS ANALYSIS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS DUAL BRONCHODILATOR THERAPY (UMEC/VI) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN

    Nov 1, 2019, 00:00

  • PDB117 PATIENT TREATMENT SATISFACTION AND STUDY STAFF PERCEPTIONS OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES

    Nov 1, 2019, 00:00

  • PIN85 POTENTIAL PUBLIC HEALTH IMPACT OF REACHING THE WHO/EU TARGET OF 75% INFLUENZA VACCINATION COVERAGE AMONG THE ELDERLY IN GERMANY

    Nov 1, 2019, 00:00

  • PRO40 BUDGET IMPACT ANALYSIS OF IDURSULFASE BETA IN THE TREATMENT MUCOPOLYSACCHARIDOSIS TYPE II IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00

  • PMH23 A RETROSPECTIVE CHART REVIEW STUDY TO QUANTIFY THE MONTHLY MEDICAL RESOURCE USE AND COSTS OF TREATING PATIENTS WITH TREATMENT RESISTANT DEPRESSION IN THE UNITED KINGDOM

    Nov 1, 2019, 00:00

  • PNS304 IN SEARCH OF A PAN-EUROPEAN VALUE SET; APPLICATION FOR EQ-5D-3L: THE PECUNIA PROJECT

    Nov 1, 2019, 00:00

  • PMH24 DEPENDENCE AS A MEASURE OF HEALTH BENEFIT IN THE ECONOMIC EVALUATION OF DEMENTIA INTERVENTIONS

    Nov 1, 2019, 00:00

  • PCV139 EUROPEAN SURVEY ON STABLE ANGINA: REAL WORLD INSIGHTS ON PATIENTS’ CHARACTERISTICS, PERCEPTION OF DISEASE, AND QUALITY OF LIFE

    Nov 1, 2019, 00:00

  • PND70 NARCOLEPSY TREATMENT IN SWEDEN: REGISTER BASED STUDY

    Nov 1, 2019, 00:00

  • PIN109 DETERMINING THE BURDEN OF CARBAPENEM-RESISTANT GRAM-NEGATIVE INFECTIONS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

    Nov 1, 2019, 00:00

  • PMU118 USE OF COMPUTER-ASSISTED METHODS TO REALIZE THE CONCEPT OF A LIVING SYSTEMATIC REVIEW VIA AN ONLINE PLATFORM

    Nov 1, 2019, 00:00

  • PCN181 ACCELERATING EARLY COST-EFFECTIVENESS MODELING IN ONCOLOGY USING AN INDICATION-AGNOSTIC WEB-BASED PLATFORM: A RETROSPECTIVE CASE STUDY OF NIVOLUMAB PRE-TREATED METASTATIC SMALL-CELL LUNG CANCER POPULATION

    Nov 1, 2019, 00:00

  • PCN382 TRASTUZUMAB IN THE TREATMENT OF HER2-POSITIVE EARLY ANDLOCALLY ADVANCED BREAST CANCER: THE FIRST HTA REPORT OF INEAS-TUNISIA

    Nov 1, 2019, 00:00

  • PNS100 A STUDY OF KNOWLEDGE, ATTITUDE AND PRACTICE REGARDING ADMINISTRATION OF PAEDIATRIC DOSAGE FORMS

    Nov 1, 2019, 00:00

  • PNS183 UNIVERSAL HEALTH INSURANCE COVERAGE FOR CHILDREN UNDER AGE 6: FACTORS ASSOCIATED WITH THE USE OF PRIVATE OVER PUBLIC HEALTH SERVICES IN VIETNAM

    Nov 1, 2019, 00:00

  • PCN413 A BAYESIAN MIXTURE CURE MODEL USING INFORMATIVE PRIORS

    Nov 1, 2019, 00:00

  • PCN5 REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

    Nov 1, 2019, 00:00

  • PNS279 ASSESSING THE LIKELIHOOD OF RECEIVING A POSITIVE RECOMMENDATION THROUGH NICE'S STA PROCESS IN LINE WITH THE INDICATED PATIENT POPULATION

    Nov 1, 2019, 00:00

  • PRO131 WHAT DO WE KNOW ABOUT PATIENT'S AND CAREGIVERS' EXPERIENCE WHEN LIVING WITH THE HEREDITARY RETINAL CONDITION RETINITIS PIGMENTOSA?

    Nov 1, 2019, 00:00

  • PNS415 PUBLISHING OBSERVATIONAL STUDIES VS RANDOMIZED CONTROLLED TRIALS - A PUBMED REVIEW

    Nov 1, 2019, 00:00

  • PIH18 PREDICTED COST AND CAPACITY BENEFITS OF THE DIGITALIZED SECONDARY CARE PATH FOR WOMEN WITH ENDOMETRIOSIS @ VIRTUAL HOSPITAL 2.0

    Nov 1, 2019, 00:00

  • Toward a Smaller Design for EQ-5D-5L Valuation Studies

    Nov 1, 2019, 00:00

  • Sensory System Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00

  • CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

    Nov 1, 2019, 00:00

  • Mental Health - Health Technology Assessment

    Nov 1, 2019, 00:00

  • PCN317 VALIDATION OF A STANDARD SET OF PATIENT-CENTERED OUTCOMES FOR LUNG CANCER IN SPAIN

    Nov 1, 2019, 00:00

  • PCN161 COST-EFFECTIVENESS OF FOLFIRI + CETUXIMAB VS. FOLFIRI + BEVACIZUMAB IN FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER WITH LEFT-SIDED PRIMARY TUMOUR LOCATION IN ITALY: A COUNTRY ADAPTATION BASED ON THE FIRE-3 ...

    Nov 1, 2019, 00:00

  • PND16 A SEMI-STANDARDIZED SYMPTOM MENU TO FACILITATE GOAL ATTAINMENT SCALING IN DEMENTIA DRUG TRIALS: COMPARISON WITH TRADITIONAL APPROACHES

    Nov 1, 2019, 00:00

  • PPM4 COMPREHENSIVE GENOMIC PROFILING FOR NON-SMALL CELL LUNG CANCER (NSCLC): A HEALTH AND BUDGET IMPACT ANALYSIS

    Nov 1, 2019, 00:00

  • PDG106 EFFECTS OF STATIN THERAPY ON LONG-TERM HEALTH CARE OUTCOMES AND MEDICAL COST-BASED ON CHINA REGIONAL HEALTH INSURANCE CLAIM DATABASE

    Nov 1, 2019, 00:00

  • SP3 PATIENTS' PREFERENCES FOR BREAST CANCER TREATMENTS: RESULTS OF A DISCRETE CHOICE EXPERIMENT (DCE) SURVEY FROM SPAIN, FRANCE, POLAND AND IRELAND

    Nov 1, 2019, 00:00

  • PRO68 A SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

    Nov 1, 2019, 00:00

  • PRS23 COST-EFFECTIVENESS OF TIOTROPIUM + OLODATEROL VERSUS ACLIDINIUM + FORMOTEROL FIXED-DOSE COMBINATIONS IN THE MANAGEMENT OF MODERATE-TO-SEVERE COPD IN IRAN

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Epidemiology Public Health

    Nov 1, 2019, 00:00

  • PDG29 ORPHAN DRUGS ASSESMENT IN FRANCE: ACCEPTABILITY OF THE CLINICAL DATA FOR THE ECONOMIC EVALUATION

    Nov 1, 2019, 00:00

  • PDG46 DOES NEW WAY TO IMPROVE PATIENTS ACCESS TO EXPENSIVE INNOVATIVE DRUGS IN POLAND WORK?

    Nov 1, 2019, 00:00

  • PNS308 METHODOLOGICAL APPROACHES FOR INCORPORATING INVESTIGATORS' CHOICE COMPARATOR ARMS INTO NETWORK META-ANALYSES

    Nov 1, 2019, 00:00

  • PBI55 FUTURE TRENDS ON THE BIOSIMILAR UPTAKE IN THE EU5 AND THE US

    Nov 1, 2019, 00:00

  • PCN39 TREATMENT PATTERNS, MINIMAL RESIDUAL DISEASE (MRD) TESTING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PATIENT CHART REVIEW IN BELGIUM, GREECE AND SWITZERLAND

    Nov 1, 2019, 00:00

  • PSU26 ANALYSIS THE PROGRESSION OF MARKET SHARE OF ONE-DAY SURGERY AMONG HUNGARIAN UNIVERSITIES

    Nov 1, 2019, 00:00

  • PNS355 HOW INVOLVED SHOULD PAYERS BE IN THE DEVELOPMENTS OF TARGET PRODUCT PROFILE (TPP), PRODUCT DEVELOPMENT PLAN (PDP) AND DESIGN OF CLINICAL TRIALS (DOCT)

    Nov 1, 2019, 00:00

  • PDB107 A COMPARISON BETWEEN THE EQ-5D-5L AND THE SF-6D IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2019, 00:00

  • PNS70 THE EFFECT OF OUT-OF-POCKET HEALTHCARE PAYMENT ON THE FINANCES OF NIGERIAN FAMILIES

    Nov 1, 2019, 00:00

  • PMU83 PATIENT-FOCUSED OUTCOMES IN THE AMNOG-PROCESS - STATUS QUO AND QUO VADIS

    Nov 1, 2019, 00:00

  • PCN288 HOW IS METASTATIC MELANOMA TREATED IN THE PUBLIC HEALTH SYSTEM IN BRAZIL?: A CALL FOR CHANGE

    Nov 1, 2019, 00:00

  • PCN86 HEALTHCARE RESOURCE UTILIZATION FOR CETUXIMAB + CHEMOTHERAPY ADMINISTERED EVERY OTHER WEEK VS ONCE WEEKLY FOR TREATMENT OF METASTATIC COLORECTAL CANCER: REAL-WORLD OUTCOMES FROM A US CLAIMS DATABASE STUDY

    Nov 1, 2019, 00:00

  • PNS394 DEVELOPMENT OF A MULTIPLICATIVE MULTI-ATTRIBUTE AND SINGLE-ATTRIBUTE UTILITY FUNCTION FOR THE HUI3 IN JAPAN

    Nov 1, 2019, 00:00

  • PCV20 MACHINE LEARNING BETTER PREDICTS RISK AFTER ACUTE CORONARY SYNDROMES, IDENTIFIES HIGH-COST INDIVIDUALS AND THOSE WITH ELEVATED BURDEN OF UNCONTROLLED RISK FACTORS

    Nov 1, 2019, 00:00

  • PDB59 EVALUATING THE COST-UTILITY OF ADDING SODIUM-GLUCOSE COTRANSPORTER INHIBITORS TO A BASAL-BOLUS INSULIN REGIMEN IN PATIENTS WITH TYPE 1 DIABETES IN THE UK: AN ANALYSIS USING THE PRIME DIABETES MODEL

    Nov 1, 2019, 00:00

  • PNS259 NATIONAL HTA IMPLEMENTATION IN MIDDLE-INCOME COUNTRIES, THE CASE OF JORDAN

    Nov 1, 2019, 00:00

  • PMS55 TREATMENT PATTERNS AMONG MS PATIENTS NEWLY INITIATING DISEASE-MODIFYING THERAPY

    Nov 1, 2019, 00:00

  • PCN81 COST-EFFECTIVENESS OF DABRAFENIB AND TRAMETINIB COMPARED TO PEMBROLIZUMAB AS ADJUVANT TREATMENT OF STAGE III HIGH-RISK BRAF V600E MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION: A BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Nov 1, 2019, 00:00

  • PAM6 BUDGET IMPACT ANALYSIS OF THE ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN OBESE PATIENTS IN ITALY

    Nov 1, 2019, 00:00

  • PNS179 HOW DOES EXTERNAL REFERENCE PRICING FOR MEDICARE PART B DRUGS COMPARE TO OTHER COST METRICS AVAILABLE IN THE UNITED STATES?

    Nov 1, 2019, 00:00

  • PRS30 PRAGMATIC META-ANALYSIS OF PROPORTIONAL ASSIST VENTILATION+ VERSUS PRESSURE SUPPORT VENTILATION AND ITS IMPACT ON COST EFFECTIVENESS

    Nov 1, 2019, 00:00

  • Cardiovascular Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PND63 ASSOCIATION BETWEEN TYPE OF SURGERY AND DEVELOPMENT OF PARKINSON'S DISEASE: A NESTED CASE-CONTROL STUDY USING A US INSURANCE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PCV101 REAL-WORLD COST AND EFFECTIVENESS ANALYSIS OF POST-ACUTE CARE VS. NON-PAC FOR STROKE PATIENTS AFTER DISCHARGE FROM HOSPITAL

    Nov 1, 2019, 00:00

  • PDG70 KNOWLEDGE, ATTITUDES AND PRACTICES OF MOROCCAN COMMUNITY PHARMACISTS TOWARDS THE THIRD-PARTY PAYER SYSTEM

    Nov 1, 2019, 00:00

  • PND26 ECONOMIC BURDEN OF HUNTINGTON'S DISEASE IN EUROPE

    Nov 1, 2019, 00:00

  • PNS306 USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE AS A REVIEWER FOR A SYSTEMATIC LITERATURE REVIEW OF RANDOMIZED CONTROLLED TRIALS

    Nov 1, 2019, 00:00

  • PNS318 NETWORK META-ANALYSES COMBINING RANDOMIZED AND NON-RANDOMIZED EVIDENCE; A NICE HTA REVIEW

    Nov 1, 2019, 00:00

  • PNS241 EXPERIENCE AND IMPACT OF NICE SCIENTIFIC ADVICE: 10 YEARS ON

    Nov 1, 2019, 00:00

  • PBI67 METHODOLOGICAL DESIGN OF ADVANCED INTERVENTIONAL TRIALS FOR GENE THERAPIES

    Nov 1, 2019, 00:00

  • PCN484 SYSTEMATIC REVIEW OF A DISEASE-SPECIFIC PATIENT-REPORTED OUTCOME MEASURE IN PATIENTS WITH MULTIPLE MYELOMA: EORTC QLQ-MY20 INSTRUMENT DEVELOPMENT AND VALIDATION

    Nov 1, 2019, 00:00

  • PCN517 VARIABILITY OF COST TRAJECTORIES OVER THE LAST YEAR OF LIFE; AN EXPLORATIVE STUDY IN PATIENTS WITH ADVANCED BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2019, 00:00

  • PCN188 THE COST-EFFECTIVENESS OF PARENTERAL NUTRITION IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCV42 COST-EFFECTIVENESS ANALYSIS OF APIXABAN COMPARED TO OTHER DOACS FOR PREVENTION OF STROKE IN AUSTRIAN ATRIAL FIBRILLATION PATIENTS

    Nov 1, 2019, 00:00

  • PRO27 IMPLICATIONS OF INDICATION EXPANSION OF ORPHAN DESIGNATED DRUGS ON EXISTING PRICES ACROSS EUROPEAN MARKETS

    Nov 1, 2019, 00:00

  • PCV107 HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENT IN PATIENTS WITH HYPERTENSION IN HONG KONG (HK) SAR,CHINA

    Nov 1, 2019, 00:00

  • PNS409 ANALYSIS OF EPIDEMIOLOGY AND PHARMACOUTILIZATION ON PATIENTS AFFECTED BY OPHTHALMIC DISEASES WITH INDICATIONS FOR INTRAVITREAL TREATMENTS IN A NORTHERN ITALIAN REGION

    Nov 1, 2019, 00:00

  • PCN49 INDIRECT COMPARISON OF HRQOL DATA FOR PATIENTS WITH TREATMENT-REFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE REGORAFENIB (CORRECT TRIAL)

    Nov 1, 2019, 00:00

  • Neurological Disorders - Methodological Statistical Research

    Nov 1, 2019, 00:00

  • Drugs Generics - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS284 IS THERE A NEED FOR REAL WORLD EVIDENCE (RWE) IN HEALTH TECHNOLOGY ASSESSMENTS OF RARE DISEASES AND ONCOLOGY TREATMENTS?

    Nov 1, 2019, 00:00

  • Artificial Intelligence Studies

    Nov 1, 2019, 00:00

  • PCN339 INCORPORATING COMPANION DIAGNOSTICS (CDX) IN COST-EFFECTIVENESS MODELS (CEMS) SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE). A REVIEW

    Nov 1, 2019, 00:00

  • PDG8 SYNCHRONISING MARKET AND BRAND SHAPING ACTIVITIES: THE IMPORTANCE OF POLICY AND BRAND ALIGNMENT

    Nov 1, 2019, 00:00

  • PSY21 COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL

    Nov 1, 2019, 00:00

  • PIH6 METABOLICS SYNDROME AND COMPLICATIONS PREGNANT WITH PCOS

    Nov 1, 2019, 00:00

  • PBI50 LEVERAGING OUTCOME BASED AND PORTFOLIO AGREEMENTS TO GUARANTEE CLINICAL OUTCOMES: INNOVATIVE PAYMENT MODELS FOR HIGH COST ONE-TIME TREATMENTS

    Nov 1, 2019, 00:00

  • PND107 NEUROLOGIST AND PATIENT PREFERENCES IN MULTIPLE SCLEROSIS: UK AND US QUALITATIVE RESEARCH FINDINGS

    Nov 1, 2019, 00:00

  • Musculoskeletal Disorders - Economic Evaluation

    Nov 1, 2019, 00:00

  • PCN378 PHARMACOECONOMIC ANALYSIS OF ATEZOLIZUMAB PLUS NAB-PACLITAXEL IN THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER

    Nov 1, 2019, 00:00

  • PNS185 RELATIONSHIP BETWEEN PARTIAL VALUES AND SCORING SCALE FOR EACH CRITERION OF THE EVIDEM 10TH EDITION CORE MODEL IN JAPAN

    Nov 1, 2019, 00:00

  • PCN294 THE IMPACT OF VALUE-BASED CARE ON ONCOLOGY SPECIALTY PHYSICIANS

    Nov 1, 2019, 00:00

  • PDG88 COST-UTILITY ANALYSIS OF ABIRATERONE VERSUS ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF ANDROGEN DEPRIVATION THERAPY

    Nov 1, 2019, 00:00

  • PDG79 WAS THE EVIDENCE BASE FOR YESCARTA AND KYMRIAH SUFFICIENT TO JUSTIFY THEIR COST AND SECURE PATIENT ACCESS ACROSS 5 MARKETS?

    Nov 1, 2019, 00:00

  • RARE Orphan Diseases - Clinical Outcomes

    Nov 1, 2019, 00:00

  • PNS25 EVALUATION OF THE SCIENTIFIC ACTIVITY OF MEDICAL UNIVERSITIES AND RESEARCH CENTERS TO CREATE THE NATIONAL STRATEGY OF THE MEDICAL SCIENCE DEVELOPMENT

    Nov 1, 2019, 00:00

  • Diabetes/Endocrine/Metabolic Disorders - Medical Technologies

    Nov 1, 2019, 00:00

  • PCN280 CHARACTERIZING THE CONTINUED RELEVANCE OF IRP IN ITALY: A SIMULATION ANALYSIS OF TOP PRESCRIBED MOLECULES IN ONCOLOGY

    Nov 1, 2019, 00:00

  • PCN106 A REVIEW OF DECISION ANALYTIC MODELS TO EVALUATE THE COST-EFFECTIVENESS OF CANCER TREATMENTS: 5-YEARS OF PUBLICATIONS AND SINGLE-TECHNOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PSU9 COSTS OF STOMA MANAGEMENT POST COLORECTAL SURGERY IN THE UK HEALTHCARE SYSTEM AND IMPLICATIONS OF POTENTIAL REDUCTION IN NEED FOR OSTOMY PLACEMENT

    Nov 1, 2019, 00:00

  • PDG43 ARE PATIENT ACCESS SCHEMES AND COMMERCIAL ACCESS AGREEMENTS ESSENTIAL FOR NICE TO RECOMMEND ACCESS? A COMPARISON OF ONCOLOGY AND NON-ONCOLOGY APPRAISALS

    Nov 1, 2019, 00:00

  • PCN266 PATIENT, DISEASE CHARACTERISTICS AND TREATMENT PATTERNS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN GREECE: RESULTS FROM ANALYSIS OF A GREEK CLL-DATABASE

    Nov 1, 2019, 00:00

  • PNS198 PHARMACY COST OF PREVENTING ADVERSE DRUG EVENTS BY PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS

    Nov 1, 2019, 00:00

  • PCN267 PREVALENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: A COMPARATIVE ANALYSIS OF CLAIMS DATA AND REGISTRY DATA IN GERMANY

    Nov 1, 2019, 00:00

  • PNS245 SNAPSHOT OF EARLY ACCESS PROGRAMMES IN PORTUGAL: A NEW ACCESS HURDLE?

    Nov 1, 2019, 00:00

  • PCN403 IDENTIFYING KEY CRITERIA FOR HEALTH TECHNOLOGY ASSESSMENT FOR ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL: A MCDA APPROACH

    Nov 1, 2019, 00:00

  • PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE

    Nov 1, 2019, 00:00

  • PNS238 THE CHANGING DYNAMICS OF PATIENT ACCESS SCHEMES IN ENGLAND

    Nov 1, 2019, 00:00

  • PDG81 EARLY HEALTH TECHNOLOGY ASSESSMENT (HTA): LESSONS LEARNED FROM A RUSSIAN BIOTECHNOLOGY COMPANY

    Nov 1, 2019, 00:00

  • PGI50 THE RELATIONSHIP BETWEEN DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN

    Nov 1, 2019, 00:00

  • PIT9 IMPACT OF FALLS IN THE ELDERLY POPULATION FOR THE SPANISH NATIONAL HEALTH SYSTEM

    Nov 1, 2019, 00:00

  • PBI35 HEALTH ECONOMICS MODELLING FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP): A TARGETED LITERATURE REVIEW (LR)

    Nov 1, 2019, 00:00

  • PRS39 THE ECONOMIC BURDEN OF ASTHMA

    Nov 1, 2019, 00:00

  • PMU121 CRITICAL REVIEW OF VALIDATION STUDIES OF ARTIFICIAL INTELLIGENCE TECHNOLOGIES APPLIED IN MEDICINE DURING THE LAST FIVE YEARS

    Nov 1, 2019, 00:00

  • PND73 FACTORS INFLUENCING INTENTION TO ENGAGE IN PREVENTIVE BEHAVIORS FOR ALZHEIMER'S DISEASE: A PROTECTION MOTIVATION THEORY APPROACH

    Nov 1, 2019, 00:00

  • PCN295 THE BEHAVIOUR OF THE CANCER DRUGS FUND (CDF) OVER TIME; THE IMPACT OF INNOVATIVE THERAPIES AND IMPLICATIONS FOR MANAGED ENTRY AGREEMENTS

    Nov 1, 2019, 00:00

  • PBI74 MARKET ACCESS LANDSCAPE FOR BIOSIMILARS IN SWEDEN: AN UNTAPPED POTENTIAL?

    Nov 1, 2019, 00:00

  • PCN175 BUDGET IMPACT ANALYSIS OF THE INCORPORATION OF MIDOSTAURIN FOR FLT3-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM (BPHS).

    Nov 1, 2019, 00:00

  • PNS248 DOES THE EVALUATION OF THE FRENCH TRANSPARENCY COMMITTEE (TC) ON DRUG EFFECTIVENESS HAVE AN IMPACT ON THE HEALTH-ECONOMIC EVALUATION CONDUCTED BY THE FRENCH ECONOMIC AND PUBLIC HEALTH ASSESSMENT COMMITTEE (CEESP)?

    Nov 1, 2019, 00:00

  • PIN32 A PUBLIC HEALTH AND BUDGET IMPACT ANALYSIS (BIA) OF VACCINATING ADULTS AGAINST PNEUMOCOCCAL-DISEASES IN AUSTRIA

    Nov 1, 2019, 00:00

  • PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

    Nov 1, 2019, 00:00

  • PCV44 COST ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ROSUVASTATIN AND EZETIMIBE IN THE GREEK SETTING

    Nov 1, 2019, 00:00

  • PNS246 EMA G-BA - A COMPARISON OF TIME LIMITATIONS OF EUROPEAN MARKETING AUTHORIZATIONS AND GERMAN ADDED BENEFIT ASSESSMENTS FOR NEW PHARMACEUTICALS.

    Nov 1, 2019, 00:00

  • PDG30 PHARMACOECONOMIC EVALUATION OF ANTI-VEGF DRUGS AND LASER PHOTOCOAGULATION FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CHINA

    Nov 1, 2019, 00:00

  • PND114 REAL WORLD PATIENT SURVEY ON HOW MIGRAINE AFFECTS EGYPTIAN SOCIAL AND WORK LIFE

    Nov 1, 2019, 00:00

  • PDG69 DEVELOPMENT OF LISTS OF TOPICAL ANTIFUNGAL DRUGS INCLUDED INTO THE ALL EDITIONS OF STATE FORMULARY OF UKRAINE

    Nov 1, 2019, 00:00

  • Drugs Statistical Research

    Nov 1, 2019, 00:00

  • PCN73 ECONOMIC EVALUATION OF TARGETED TREATMENTS FOR BRAFV600 POSITIVE MELANOMA IN THE IRISH HEALTHCARE SETTING

    Nov 1, 2019, 00:00

  • TP3 CHARACTERIZING AND COMPARING US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY RECEIPT OF MEDICATION-ASSISTED TREATMENT (MAT)

    Nov 1, 2019, 00:00

  • PCN424 NETWORK META-ANALYSIS FOR IMMUNE ONCOLOGY TRIALS USING SPLINES

    Nov 1, 2019, 00:00

  • PDG73 INCLUSION OF ADVERSE EVENTS IN THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: A REVIEW OF THE MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

    Nov 1, 2019, 00:00

  • PRO121 THE USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT OF MEDICATIONS FOR RARE DISEASES

    Nov 1, 2019, 00:00

  • PDB20 EMPAGLIFLOZIN VS SITAGLITPIN, SAXAGLIPTIN AND LIRAGLUTIDE IN SPAIN. A BUDGET IMPACT MODEL BASED ON THE CORE DIABETES MODEL AND CARDIOVASCULAR OUTCOMES TRIALS

    Nov 1, 2019, 00:00

  • Gastrointestinal Disorders - Health Technology Assessment

    Nov 1, 2019, 00:00

  • NO Specific Disease - Medical Technologies

    Nov 1, 2019, 00:00

  • PSU41 COMPLIANCE WITH SURGICAL ANTIBIOTIC PROPHYLAXIS FOR OBSTETRIC AND GYNECOLOGIC SURGERIES IN NIGERIA: A RETROSPECTIVE STUDY

    Nov 1, 2019, 00:00

  • PCN345 A REVIEW OF DIFFERENCES IN DECISION-MAKING ACROSS NICE HEALTH TECHNOLOGY ASSESSMENTS OF NIVOLUMAB

    Nov 1, 2019, 00:00

  • PSY48 DO CLINICAL AND DEMOGRAPHIC CHARACTERISTICS AFFECT PATIENT PREFERENCE HETEROGENEITY FOR PSORIASIS TREATMENTS? RESULTS FROM A DISCRETE-CHOICE EXPERIMENT IN A MULTICOUNTRY STUDY

    Nov 1, 2019, 00:00
  • «
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47 (current)
  • 48
  • 49
  • 50
  • »